Traditional Chinese medicine composition for treating hand-foot skin reaction and preparation method thereof

Through a traditional Chinese medicine composition containing angelica, honeysuckle, kennellia, angelica, angelica, licorice, purpura, frankincense and myrrh, combined with a paste preparation of Vaseline or sesame oil and beeswax, the problem of low efficacy of skin reaction in the prior art is solved. , and the effect of significantly reducing the severity of reaction and improving the quality of life is achieved.

CN118924834AActive Publication Date: 2024-11-12JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411118482.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-12
Estimated Expiration
2044-08-14

AI Technical Summary

Technical Problem

The prior art has low efficacy in treating hand and foot skin reactions (HFSR), cannot effectively relieve pain and comorbid symptoms, and lacks prevention and treatment recommendations based on high-level evidence.

Method used

Provided a traditional Chinese medicine composition, including angelica, honeysuckle, kennellia, angelica, licorice, purpura, frankincense and myrrh, to make a paste preparation by specific extraction and preparation methods, combining Vaseline or sesame oil and beeswax as auxiliary materials, for use in Treatment of skin reactions in the hands and feet.

Benefits of technology

It significantly reduces the incidence and severity of skin reactions in the hands and feet, improves pain and co-morbid symptoms, such as itching and swelling, improves the patient's quality of life, and ensures the continued anti-tumor treatment, and is safe.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924834A_ABST
    Figure CN118924834A_ABST
Patent Text Reader

Abstract

The invention provides a traditional Chinese medicine composition for treating hand-foot skin reaction and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition consists of the following components: angelica sinensis, honeysuckle, polygonum cuspidatum, radix angelicae, liquorice, lithospermum, frankincense, myrrh and dragon's blood, and has the effects of clearing away heat and toxic materials, activating blood and promoting tissue regeneration. The traditional Chinese medicine composition shows a good curative effect in clinical application of treating hand-foot skin reaction caused by chemotherapeutic drugs and targeted drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating hand-foot skin reactions and a preparation method thereof. Background Art

[0002] Chemotherapy and targeted therapy are important methods in anti-tumor treatment. The most common skin adverse reaction is hand-foot skin reaction (HFSR). The incidence may be closely related to the type of drug, the number of times of administration, and the mode of administration. It mainly manifests as sensitivity, tingling, burning, erythema and swelling, thickening, roughness, cracking, desquamation and severe pain in the hands and feet. The severity varies slightly with the type of drug, and it is a dose-limiting toxicity. Common drugs that cause HFSR include cytotoxic chemotherapy drugs such as capecitabine, fluorouracil, liposomal doxorubicin, docetaxel, and multikinase inhibitors such as regorafenib, sorafenib, and sunitinib. It can also be seen in EGFR inhibitors (erlotinib, gefitinib), BRAF inhibitors (vemurafenib, dabrafenib), etc.

[0003] Hand and foot skin reactions have a great impact on patients. On the one hand, lesions on the hands and feet are difficult to cover with clothes. On the other hand, hands and feet are closely related to life, which seriously affects patients' emotions (86.11%), social entertainment (73.41%), living habits (73.58%), disease treatment (48.03%) and intimate relationships (45.97%), increases patients' psychological burden and sleep disorders, and when patients have grade II or above skin adverse reactions, 80.09% of doctors will make adjustments to reduce or terminate the drug regimen, which has a great negative impact on patients' anti-tumor treatment, quality of life, and physical and mental health.

[0004] At present, the pathogenesis of HFSR is still unclear. Analysis shows that it may be related to factors such as keratinocyte dysfunction, crosstalk between vascular endothelial cells and keratinocytes, and sweat gland excretion. Studies have shown that oral drugs such as celecoxib, dexamethasone, pyridoxine, and vitamin B6, and topical drugs such as moisturizers, hydrocolloid excipients, and clobetasol ointment have a certain effect on the prevention and treatment of HFSR, but there are also controversies; among them, urea ointment has a good preventive effect on HFSR, significantly reducing the incidence of HFSR (56% vs 73.6%, P<0.01) and prolonging the median time of occurrence. However, for the treatment of HFSR, there are still disadvantages such as low overall efficacy and no obvious improvement in the combined symptoms of HFSR such as pain and itching. Reduction or discontinuation of targeted drugs is still the most effective treatment for HFSR. So far, there is no high-level evidence-based recommendation for the prevention and treatment of HFSR at home and abroad. Research and development of drugs for the prevention and treatment of HFSR has important clinical significance and application prospects. Summary of the invention

[0005] In view of this, the object of the present invention is to provide a Chinese medicine composition for treating hand-foot skin reaction and a preparation method thereof, which can be well applied in drugs for treating hand-foot skin reaction and has good therapeutic effect.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a traditional Chinese medicine composition for treating hand-foot skin reaction, comprising the following components in parts by weight:

[0008] 50-150 parts of angelica sinensis, 50-150 parts of honeysuckle, 100-200 parts of knotweed, 40-80 parts of angelica dahurica, 20-60 parts of liquorice, 50-150 parts of lithospermum, 10-50 parts of frankincense, 10-50 parts of myrrh, and 5-15 parts of dragon's blood.

[0009] The present invention also provides a Chinese medicine preparation for treating hand-foot skin reaction, comprising the Chinese medicine composition and auxiliary materials;

[0010] The excipients are vaseline and ethylparaben solution;

[0011] Or sesame oil and beeswax.

[0012] The present invention also provides a method for preparing the Chinese medicine preparation. When the auxiliary materials are vaseline and ethylparaben solution, the preparation method is as follows:

[0013] A. Mix angelica sinensis, honeysuckle, knotweed, angelica dahurica, liquorice and lithospermum officinale with 5 to 10 times the volume of 50 to 80% ethanol solution, reflux extraction 1 to 3 times, each time for 40 to 80 minutes, combine the extracts, and concentrate the extracts to a fluid extract with a relative density of 1.14 to 1.20;

[0014] B. Freeze frankincense and dragon's blood, mix them, grind them, and sieve them to obtain frankincense-dragon's blood powder, and grind myrrh separately, and sieve them to obtain myrrh powder;

[0015] Or, frankincense and myrrh are crushed and sieved, 10 to 14 times the mass of ethanol with a volume concentration of 80 to 100% is added for percolation, the percolation liquid is collected, and concentrated to a relative density of 1.00 to 1.15 to obtain a frankincense-myrrh percolation concentrate, and dragon's blood is crushed and sieved to obtain dragon's blood powder;

[0016] C. adding the fluid extract described in step A to 1500-2200 parts of melted vaseline for homogenization to obtain a matrix;

[0017] D. mixing the frankincense-dragon blood powder, myrrh powder, ethylparaben solution and the matrix described in step B and cooling the mixture;

[0018] Alternatively, the frankincense-myrrh percolated concentrate, dragon's blood powder, ethylparaben solution and the matrix described in step C are mixed and cooled to obtain the product.

[0019] Preferably, the sieving is through a 100-200 mesh sieve.

[0020] Preferably, the temperature of the vaseline is 45-60°C.

[0021] Preferably, the mass ratio of the total amount of frankincense-dragon blood powder and myrrh powder to the ethylparaben solution is 15-25:1, and the concentration of the ethylparaben solution is 1-3%.

[0022] Preferably, the concentration temperature in step B is 50-60°C.

[0023] The present invention also provides a method for preparing the Chinese medicine preparation. When the auxiliary materials are sesame oil and beeswax, the preparation method is as follows:

[0024] a. Soak Chinese angelica, honeysuckle, knotweed, angelica dahurica and licorice in 1500-2500 parts of sesame oil for 2-5 days;

[0025] b. After soaking, heat to 100-160°C, hold for 20-60min, filter, and collect the liquid component; add lithospermum to the liquid component, heat to 140-180°C, fry for 10-30min, filter out the residue, and obtain filtered oil;

[0026] c. Keep the oil temperature at 110-135°C, add 300-700 parts of beeswax, stir for 3-8 minutes until the beeswax is completely melted, and then cool to 40-55°C;

[0027] d. Add crushed and sieved frankincense, dragon's blood and myrrh powder, stir well.

[0028] The present invention also provides application of the traditional Chinese medicine composition in preparing medicine for treating hand-foot skin reaction.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] The invention provides a Chinese medicine composition for treating hand and foot skin reaction, which is an exploratory improvement on the famous prescription Yuhong Shengji ointment of the sore department, removes the mercury-containing toxic substance calomel, adds honeysuckle and knotweed for clearing heat and cooling blood, removing dampness and detoxifying, and adds frankincense and myrrh for relieving pain, and has the effects of clearing heat and detoxifying, promoting blood circulation and promoting muscle growth. The main medicines of this prescription, angelica and honeysuckle, can promote blood circulation and relieve pain, clear heat and detoxify; the subordinates, knotweed, frankincense and myrrh, can cool blood and detoxify, disperse blood stasis and relieve pain, and reduce swelling and promote muscle growth; the auxiliary medicines, angelica, blood clotting and lithospermum, can dispel wind and relieve pain, promote muscle growth and heal sores, help relieve swelling and itching, and help repair; the auxiliary medicines, licorice, can clear heat and detoxify, and harmonize various medicines. Modern pharmacological research also shows that various drugs in this prescription have the effects of anti-oxidation, anti-inflammatory and antibacterial, promoting blood circulation and relieving pain, and anti-tumor. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Flowchart for inclusion of cases;

[0032] Figure 2 The patient's medication status;

[0033] Figure 3 The NCI classification changes for each evaluation node (vertical axis units as an example);

[0034] Figure 4 The change of NRS grade of pain before and after treatment;

[0035] Figure 5 This is a comparison chart of the treatment effects of HFSR caused by taking apatinib;

[0036] Figure 6 This is a comparison chart of the treatment effects of HFSR caused by taking Segafur;

[0037] Figure 7 This is a comparison chart of the treatment effects of HFSR caused by taking liposomal doxorubicin + anlotinib. DETAILED DESCRIPTION

[0038] The present invention provides a traditional Chinese medicine composition for treating hand-foot skin reaction, comprising the following components in parts by weight:

[0039] 50 to 150 parts of Chinese Angelica sinensis, preferably 70 to 120 parts, more preferably 100 parts;

[0040] 50-150 parts of honeysuckle, preferably 70-120 parts, more preferably 100 parts;

[0041] 100-200 parts of Polygonum cuspidatum, preferably 130-170 parts, more preferably 150 parts;

[0042] 40-80 parts of Angelica dahurica, preferably 50-70 parts, more preferably 60 parts;

[0043] 20-60 parts of liquorice, preferably 30-50 parts, more preferably 40 parts;

[0044] 50-150 parts of Lithospermum officinale, preferably 70-120 parts, more preferably 100 parts;

[0045] 10 to 50 parts of frankincense, preferably 20 to 40 parts, more preferably 30 parts;

[0046] 10 to 50 parts of myrrh, preferably 20 to 40 parts, more preferably 30 parts;

[0047] 5 to 15 parts of dragon's blood, preferably 7 to 12 parts, more preferably 10 parts;

[0048] The present invention also provides a Chinese medicine preparation for treating hand-foot skin reaction, comprising the Chinese medicine composition and auxiliary materials;

[0049] The excipients are vaseline and ethylparaben solution;

[0050] Or sesame oil and beeswax.

[0051] The present invention also provides a method for preparing the Chinese medicine preparation. When the auxiliary materials are vaseline and ethylparaben solution, the preparation method is as follows:

[0052] A. Mix angelica sinensis, honeysuckle, knotweed, angelica dahurica, liquorice and lithospermum officinale with 5 to 10 times the volume of 50 to 80% ethanol solution, reflux extraction 1 to 3 times, each time for 40 to 80 minutes, combine the extracts, and concentrate the extracts to a fluid extract with a relative density of 1.14 to 1.20;

[0053] B. Freeze frankincense and dragon's blood, mix them, grind them, and sieve them to obtain frankincense-dragon's blood powder, and grind myrrh separately, and sieve them to obtain myrrh powder;

[0054] Or, frankincense and myrrh are crushed and sieved, 10 to 14 times the mass of ethanol with a volume concentration of 80 to 100% is added for percolation, the percolation liquid is collected, and concentrated to a relative density of 1.00 to 1.15 to obtain a frankincense-myrrh percolation concentrate, and dragon's blood is crushed and sieved to obtain dragon's blood powder;

[0055] C. adding the fluid extract described in step A to 1500-2200 parts of melted vaseline for homogenization to obtain a matrix;

[0056] D. mixing the frankincense-dragon blood powder, myrrh powder, ethylparaben solution and the matrix described in step B and cooling the mixture;

[0057] Alternatively, the frankincense-myrrh percolated concentrate, dragon's blood powder, ethylparaben solution and the matrix described in step C are mixed and cooled to obtain the product.

[0058] In the present invention, the amount of ethanol used in step A is preferably 5 to 10 times the total amount of angelica, honeysuckle, knotweed, angelica dahurica, licorice and lithospermum officinale, more preferably 6 to 8 times, and more preferably 7 times; the volume concentration of ethanol is preferably 50 to 80%, more preferably 60 to 70%, and more preferably 65%; the number of reflux extractions is preferably 1 to 3 times, and more preferably 2 times; the reflux extraction time for each time is preferably 40 to 80 min, more preferably 50 to 70 min, and more preferably 60 min; the density of the fluid extract is preferably 1.14 to 1.20, more preferably 1.15 to 1.18, and more preferably 1.17.

[0059] In the present invention, in step B, frankincense and Sanguis Draxonis are frozen and then mixed and crushed. The frozen and crushed treatment of frankincense and Sanguis Draxonis can reduce the difficulty of crushing, while ensuring that the effective ingredients of the medicine are not destroyed, and greatly improve the precipitation efficiency of the effective ingredients, thereby improving the therapeutic effect. Crushing frankincense and Sanguis Draxonis together can not only reduce the crosslinking degree between the crushed materials; the myrrh is crushed separately because the crushed myrrh is flocculent, which is very easy to agglomerate with other medicinal materials and difficult to sieve, so it needs to be crushed separately; the mesh number of the sieved material is preferably 100-200 meshes, more preferably 130-170 meshes, and more preferably 150 meshes. In the present invention, the amount of ethanol used in step B is preferably 10-14 times the total mass of frankincense and myrrh, more preferably 11-13 times, and more preferably 12 times, the volume concentration of ethanol is preferably 80-100%, more preferably 85-95%, and more preferably 90%, and the concentration temperature is preferably 50-60° C., more preferably 52-58° C., and more preferably 55° C.

[0060] In the present invention, the temperature of the melted vaseline is preferably 45-60°C, more preferably 50-58°C, and further preferably 55°C; the amount of vaseline used is preferably 1500-2200 parts, more preferably 1700-2000 parts, and further preferably 1900 parts.

[0061] In the present invention, the content of ethylparaben in the ethylparaben solution is preferably 1-4%, more preferably 1.5-3%, and further preferably 2%; the mass ratio of the total amount of frankincense-dragon blood powder and myrrh powder to the ethylparaben solution is preferably 15-25:1, more preferably 17-22:1, and further preferably 20:1.

[0062] The present invention also provides a method for preparing a Chinese medicine preparation. When the auxiliary materials are sesame oil and beeswax, the preparation method is as follows:

[0063] a. Soak Chinese angelica, honeysuckle, knotweed, angelica dahurica and licorice in 1500-2500 parts of sesame oil for 2-5 days;

[0064] b. After soaking, heat to 100-160°C, hold for 20-60min, filter, and collect the liquid component; add lithospermum to the liquid component, heat to 140-180°C, fry for 10-30min, filter out the residue, and obtain filtered oil;

[0065] c. Keep the oil temperature at 110-135°C, add 300-700 parts of beeswax, stir for 3-8 minutes until the beeswax is completely melted, and then cool to 40-55°C;

[0066] d. Add crushed and sieved frankincense, dragon's blood and myrrh powder, stir well.

[0067] In the present invention, the amount of sesame oil used is preferably 1500-2500 parts, more preferably 1700-2200 parts, and more preferably 2000 parts; the soaking time is preferably 2-5 days, more preferably 2.5-4 days, and even more preferably 3 days.

[0068] In the present invention, the soaking process needs to be stirred, and the stirring interval is preferably 12 to 36 hours, more preferably 20 to 30 hours, and more preferably 24 hours; after the soaking is completed, the heating temperature is preferably 100 to 160°C, more preferably 110 to 140°C, and more preferably 120°C; the heating time is preferably 20 to 60 minutes, more preferably 30 to 50 minutes, and more preferably 40 minutes; after adding lithospermum officinale, the frying temperature is preferably 140 to 180°C, more preferably 150 to 170°C, and more preferably 160°C; the frying time is preferably 10 to 30 minutes, more preferably 12 to 20 minutes, and more preferably 15 minutes.

[0069] In the present invention, after adding beeswax, the heating temperature is preferably 110-135°C, more preferably 115-125°C, and further preferably 120°C; the heating time is preferably 4-12 min, more preferably 6-10 min, and further preferably 8 min; the temperature after cooling is preferably 40-55°C, more preferably 45-52°C, and further preferably 50°C.

[0070] The invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating hand-foot skin reaction.

[0071] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0072] Example 1

[0073] A traditional Chinese medicine ointment for treating hand and foot skin reactions is prepared from the following components by weight: 1900 parts of vaseline, 100 parts of angelica sinensis, 100 parts of honeysuckle, 150 parts of knotweed, 60 parts of angelica dahurica, 40 parts of liquorice, 100 parts of lithospermum officinale, 30 parts of frankincense, 30 parts of myrrh and 10 parts of dragon's blood.

[0074] The preparation method comprises the following specific steps:

[0075] Step 1, add 7 times the mass of 65% ethanol to reflux and extract twice, each time for 1 hour, combine the extracts, recover the ethanol, and concentrate to a fluid extract with a relative density of 1.17 for standby use;

[0076] Step 2: Freeze frankincense and dragon's blood, mix and grind them, grind myrrh separately, sieve and set aside;

[0077] Step 3, adding the fluid extract into melted vaseline (temperature is 55° C.) for homogenization to obtain a matrix;

[0078] Step 4: Add frankincense-dragon blood powder, myrrh powder and 2% ethylparaben solution (the mass ratio of the total amount of frankincense-dragon blood powder and myrrh powder to the ethylparaben solution is 20:1) through a 150-mesh sieve, stir evenly, and obtain the mixture after cooling.

[0079] Example 2

[0080] A traditional Chinese medicine ointment for treating hand and foot skin reactions is prepared from the following components by weight: 1500 parts of vaseline, 60 parts of angelica sinensis, 60 parts of honeysuckle, 100 parts of knotweed, 40 parts of angelica dahurica, 30 parts of liquorice, 150 parts of lithospermum officinale, 20 parts of frankincense, 20 parts of myrrh and 10 parts of dragon's blood.

[0081] The preparation method comprises the following specific steps:

[0082] Step 1, add 7 times the mass of 65% ethanol to reflux and extract twice, each time for 1 hour, combine the extracts, recover the ethanol, and concentrate to a fluid extract with a relative density of 1.17 for standby use;

[0083] Step 2: crush the frankincense and myrrh, sieve them, add 12 times the mass of ethanol with a volume concentration of 90% to perform percolation, collect the percolation liquid, and concentrate it to a relative density of 1.00 to 1.15 to obtain the frankincense-myrrh percolation concentrate, crush the dragon's blood, and sieve it to obtain the dragon's blood powder;

[0084] Step 3, adding the fluid extract into melted vaseline (temperature is 55° C.) for homogenization to obtain a matrix;

[0085] Step 4: Mix the frankincense-myrrh percolated concentrate, dragon's blood powder, ethylparaben solution and the base, and cool the mixture to obtain the product.

[0086] Example 3

[0087] A traditional Chinese medicine ointment for treating hand and foot skin reactions is prepared from the following components by weight: 2000 parts of sesame oil, 400 parts of beeswax, 100 parts of angelica sinensis, 100 parts of honeysuckle, 150 parts of knotweed, 60 parts of angelica dahurica, 40 parts of liquorice, 100 parts of lithospermum officinale, 30 parts of frankincense, 30 parts of myrrh and 10 parts of dragon's blood.

[0088] The preparation method comprises the following specific steps:

[0089] Step 1: Soak angelica, honeysuckle, knotweed, angelica dahurica and licorice in sesame oil for three days, stirring every 24 hours;

[0090] Step 2: After soaking, heat to 130°C, keep for 30 minutes, filter and collect the liquid phase component; add lithospermum officinale to the liquid phase component, heat to 160°C, fry for 10 to 30 minutes, filter out the residue and obtain filtered oil;

[0091] Step 3: When the oil temperature drops to 120°C, add beeswax to the filtrate, heat on low heat for 5 minutes until the beeswax is completely melted, and cool to 40-55°C;

[0092] Step 4: Add the crushed and sieved frankincense, dragon's blood and myrrh powder and stir well.

[0093] Example 4

[0094] A Chinese medicinal ointment for treating hand and foot skin reactions is prepared from the following components by weight: 2200 parts of vaseline, 150 parts of angelica sinensis, 150 parts of honeysuckle, 150 parts of knotweed, 80 parts of angelica dahurica, 50 parts of liquorice, 150 parts of lithospermum officinale, 25 parts of frankincense, 25 parts of myrrh and 10 parts of dragon's blood. The preparation process is the same as that of Example 1.

[0095] Clinical trials

[0096] 1. Clinical data

[0097] 1.1 Selection of research subjects: Patients with malignant tumors who developed hand-foot skin reactions after treatment with anti-tumor drugs (targeted drugs, chemotherapy drugs) from the outpatient or inpatient departments of oncology departments of multiple centers such as Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine and Lishui District Hospital of Traditional Chinese Medicine were selected.

[0098] 1.2 Case criteria

[0099] 1.2.1 Inclusion criteria: 1) Malignant tumor confirmed by pathology; 2) Hand-foot skin reaction, which is significantly correlated with anti-tumor drugs (such as anlotinib, fruquintinib, regorafenib, capecitabine, etc.); 3) KPS score>60 points; 4) Age 18-85 years old, gender not limited; 5) Estimated survival time ≥3 months; 6) Clear consciousness and ability to judge and evaluate their own pain; 7) No local skin infection.

[0100] 1.2.2 Exclusion criteria: 1) People with hand and foot skin infections and ulcers caused by immune system diseases, severe infections, severe diabetes, etc.; 2) People with a history of severe skin diseases or those suffering from other severe skin diseases; 3) Pregnant and lactating women; 4) People who are participating in other similar hand and foot skin reaction research projects.

[0101] 1.2.3 Dropout criteria: 1) The patient withdraws the informed consent; 2) The patient experiences an adverse event (AE) that the researcher believes is necessary to terminate the trial treatment; 3) The researcher believes that, considering the patient's interests, the best option is to terminate the trial treatment; 4) The researcher believes that the patient intentionally or unintentionally fails to comply with the relevant regulations of the study; 5) The researcher believes that other situations require withdrawal from the study.

[0102] 1.3 Treatment methods

[0103] 1.3.1 Drugs

[0104] The drug prepared using Example 1 was prepared in a preparation room that met GMP standards.

[0105] 1.3.2 Dosage method: Apply evenly on the skin of the palms and soles, including the spaces between fingers and joints, three times a day.

[0106] 1.3.3 Medication duration: 4 weeks.

[0107] 1.3.4 Combined medication during the observation period

[0108] During the observation period, patients should not take other drugs for the treatment of HFSR. If the patient experiences pain or infection, symptomatic medication can be used.

[0109] 1.4 Observation indicators:

[0110] 1.4.1 Main outcome measures

[0111] HFSR severity grading: According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, the grading of patients before and after treatment was recorded. Cured: symptoms were completely relieved or the grade was reduced to grade 0; effective: the grade was reduced by ≥1 grade compared with the previous one, but not reduced to grade 0; ineffective: the grade did not change or even worsened. Total effective rate = (cured + effective) / total number of cases * 100%. Evaluation was performed before treatment, 2 weeks after treatment, and 4 weeks after treatment.

[0112] 1.4.2 Secondary Observation Index

[0113] 1) HFSR-specific quality of life scale (HFSR-14), evaluated before treatment, 2 weeks and 4 weeks after treatment; 2) Pain relief rate: double judgment using WHO pain efficacy evaluation criteria combined with NRS method, evaluated before treatment, 2 weeks and 4 weeks after treatment; 3) Anti-tumor drug completion rate: evaluated on the 28th day of treatment, considered completed if there is no reduction or discontinuation of the drug during the study. 4) HFSR common symptom scale, evaluated before treatment, 2 weeks and 4 weeks after treatment; 5) Adverse reaction evaluation: evaluated using NCI-CTC skin toxicity standards, observing whether there is rash, allergy or other subjective discomfort after the application of the present invention, evaluated before treatment, 2 weeks and 4 weeks after treatment.

[0114] 1.5 Statistical methods

[0115] All data were statistically analyzed using SPSS 26.0 software. Measurement data were expressed as mean ± standard deviation (x ± s), and count data were expressed as N (%). Count data were compared using the chi-square test, measurement data were compared using the paired T test, and rank sum test was used for rank data. All statistical analyses selected 95% as the confidence interval, P < 0.05 was considered statistically significant, and P > 0.05 was considered statistically insignificant.

[0116] 2 Research results

[0117] In the early stage of the present invention, a multicenter small-sample clinical study on the treatment of hand-foot skin reaction with the traditional Chinese medicine preparation of the present invention was carried out (Ethics Approval: 2023LWKYZ041; National Clinical Trial Platform Registration: ChiCTR2300071320). The study finally included and analyzed 58 patients.

[0118] According to statistics, half of the enrolled patients had a history of treatment for hand-foot skin reaction, such as moisturizers, ointments, silicone oil, aloe vera cream, repair cream, etc., but the treatment effect was poor. The Chinese medicine preparation of the present invention has a definite effect on the treatment of HFSR and is expected to become an effective intervention measure for HFSR.

[0119] 2.1 Case completion status

[0120] A total of 65 patients were screened in this study, 3 of whom were excluded because they did not meet the inclusion and exclusion criteria. 62 patients were included in the study, 4 of whom dropped out, with a total dropout rate of 6.45%, less than 20%. The details of the dropout cases are shown in Table 1. Finally, 58 cases were included in the statistical analysis, and all patients signed informed consent. The case inclusion flow chart is shown in the figure below. Figure 1 .

[0121] Table 1 Dropout cases

[0122]

[0123] 2.2 Baseline Analysis

[0124] Table 2 General information of patients

[0125]

[0126] The general information of the included patients is shown in Table 2: the average age of the 58 patients included in the analysis was 63.1 years old, of which the oldest patient was 89 years old and the youngest was 9 years old, and patients older than 60 years accounted for 56.9%; there were 36 male patients and 22 female patients, with a male-to-female ratio of 1.64:1; in terms of educational level, 87.9% of the patients had junior high school or below education, and only a small number of patients (12.1%) had a college education; in terms of treatment history, 46.6% of the patients had a history of previous treatment for HFSR / HFSR, including the application of moisturizers, emollients, ointments, and repair creams, but the treatment effect was not good; the study involved many types of cancer, as shown in Table 3, the most common of which was colorectal cancer, accounting for 48.3% of the total number of people, and also included lung cancer, liver cancer, breast cancer, gastric cancer, uterine cancer, esophageal cancer, and prostate cancer.

[0127] Table 3 Patients' conditions

[0128]

[0129] The patients included in the study were those who developed HFSR / HFSR after receiving anti-tumor treatment. Figure 2 : Chemotherapy drugs were used in 25 cases, accounting for 43.1% of the total; targeted drugs were used in 33 cases, accounting for 56.9%, of which one case was caused by the combination of anlotinib and vometinib, and one case was caused by the combination of anlotinib and afatinib.

[0130] Table 4 Drug treatment of patients

[0131]

[0132] 2.3 Efficacy evaluation

[0133] 2.3.1 HFSR / HFSR classification

[0134] At baseline, there were 50 patients with moderate to severe HFSR / HFSR, accounting for 86.2% of the total number of patients; at D14, there were 25 patients with moderate to severe HFSR / HFSR, accounting for 43.1% of the total number of patients; at D28, there were 13 patients with moderate to severe HFSR / HFSR, accounting for 22.4% of the total number of patients, showing an overall downward trend. Comparison of the changes in NCI grades at each assessment node before and after treatment is shown in Table 5 and Figure 3It was concluded that as the treatment time increased, the proportion of moderate to severe patients decreased, and there were significant differences between the baseline and D14 and D28 (P<0.01). Further comparison of the data between the two groups at D14 and D28 also showed statistically significant differences (P<0.01).

[0135] Table 5 NCI grading changes at each evaluation node (example)

[0136]

[0137] Comparison of the efficacy before and after treatment, as shown in Table 6 and Table 7: The effective rate of treatment D14 was significantly higher than that of treatment D7 (79.3% v 46.6%, P < 0.05), and there was also a significant difference in the efficacy level between treatment D7 and D14 (P < 0.05). There was no statistically significant difference in the effective rate and efficacy level between treatment D14 and D28 (P > 0.05).

[0138] Table 6 Comparison of therapeutic effects between D7 and D14

[0139]

[0140] Table 7 Comparison of therapeutic effects between D14 and D28

[0141]

[0142] In addition, subgroup analysis was performed according to the NCI classification, as shown in Tables 8 to 10: In terms of cure rate, the cure rate of grade II patients was significantly higher than that of grade I and grade III patients (P<0.05). In terms of effective rate, the effective rate of grade III patients was higher than that of grade I and grade II patients at D7 and D14, and the difference was statistically significant (P<0.05), but the difference was not statistically significant at D28 (P>0.05).

[0143] Table 8 Comparison of therapeutic efficacy of each NCI grade at D7

[0144]

[0145]

[0146] Table 9 Comparison of efficacy of treatment D14 in each NCI grade

[0147]

[0148] Table 10 Comparison of efficacy of treatment at D28 in each NCI grade

[0149]

[0150] Subgroup analysis was performed according to the drug treatment regimen, as shown in Table 11, and the results showed that: at D14, the effective rate of the targeted drug group was 78.8%, and the effective rate of the chemotherapy drug group was 80%, with no statistically significant difference (P>0.05); at D28, the effective rate of the targeted drug group was 81.8%, and the effective rate of the chemotherapy drug group was 87.5%, with no statistically significant difference (P>0.05).

[0151] Table 11 Comparison of efficacy of each evaluation node of HFSR / HFSR

[0152]

[0153] It can be seen from the above results that the external use of the Chinese medicine preparation of the present invention can effectively reduce the severity and NCI grade of HFSR / HFSR, especially can quickly relieve the symptoms of grade III patients and cure the symptoms of grade II patients.

[0154] 2.3.2 Pain

[0155] There were 48 patients with pain symptoms at baseline, accounting for 82.8% of the total number of patients, including 41 patients with moderate pain or above. Figure 4 It can be seen that the number of patients without pain is on the rise, while the number of patients with moderate to severe pain is on the decline.

[0156] Comparison of the changes in pain NRS grading and NRS scores before and after treatment, as shown in Tables 12 to 14, showed that there were significant differences between the baseline and D14 and D28 (P<0.05), and further comparison of the data between the two groups at D14 and D28 also showed statistically significant differences (P<0.05).

[0157] Table 12 Changes in NRS pain grading before and after treatment (cases)

[0158]

[0159] Table 13 Comparison of NRS scores at baseline and treatment D14

[0160]

[0161] Table 14 Comparison of NRS scores between treatment D14 and D28

[0162]

[0163] The pain relief rates of 48 patients with pain symptoms at baseline were compared, as shown in Table 15. The results showed that the pain relief rates on D14 were 77.1%, and the pain relief rates on D28 were 91.7%, which were higher than those on D14, and the difference was statistically significant (P<0.05).

[0164] Table 15 Comparison of pain relief between treatment D14 and D28

[0165]

[0166] 2.3.3 HFSR-14 Quality of Life

[0167] Comparing the quality of life of patients before and after treatment, as shown in Tables 16 and 17, the quality of life scores of patients improved steadily with the extension of treatment time, and the improvement at D28 was more obvious than that at D14 (P<0.05).

[0168] Table 16 Comparison of HFSR-14 scores at baseline and on treatment day 14

[0169]

[0170] Table 17 Comparison of HFSR-14 scores between treatment D14 and D28

[0171]

[0172] It can be seen from the results of pain and HFSR-14 quality of life that the external use of the Chinese medicine preparation of the present invention can effectively relieve the pain of patients and improve the quality of life of patients. In addition, long-term continuous use on an effective basis is conducive to further relieving pain and improving the quality of life.

[0173] 2.3.4 Common symptoms

[0174] Comparison of the common symptom scores of HFSR / HFSR before and after treatment, as shown in Table 18, showed that compared with the baseline, numbness, tingling, pain, dysesthesia, erythema, desquamation, pigmentation, swelling, and ulcers were significantly improved on D28 (P<0.05), but there was no statistically significant difference in the improvement of burning sensation (P>0.05).

[0175] Table 18 Comparison of common symptom scores before and after treatment

[0176]

[0177]

[0178] It can be seen from the above results that the external use of the Chinese medicine preparation of the present invention can effectively relieve clinical symptoms such as numbness, tingling, pain, insensitivity, erythema, desquamation, pigmentation, swelling, ulcers, etc. in the hands and feet of patients.

[0179] 2.4.5 Completion rate of anti-tumor drugs

[0180] Among the 58 patients included in the analysis, only 2 patients had drug reduction or discontinuation due to HFSR / HFSR, and the anti-tumor drug completion rate was 96.6%, indicating that the external use of the Chinese medicine preparation of the present invention can ensure the completion rate of anti-tumor treatment, thereby improving the treatment effect of patients.

[0181] 3.6 Adverse Reactions

[0182] The toxicity classification of the drug composition of the present invention is non-toxic according to the Chinese Pharmacopoeia, and the treatment method is external use. According to statistics, only one patient included in the study had itching, and the rest were not found to be related to the treatment, such as rash, blisters, skin redness and other toxic reactions, and the safety is good. The results show that the Chinese medicine preparation of the present invention is safe and reliable for external use, and no special serious adverse reactions occur.

[0183] 4. Analysis and explanation of research results

[0184] 4.1 Analysis of case completion status

[0185] A total of 62 patients were included in the study, reaching the planned sample size of 60. Four patients dropped out of the study, of which two were elderly patients with advanced tumors, in poor general condition, with poor compliance in applying ointments, and interrupted treatment without authorization, which can be considered as patients intentionally or unintentionally not complying with the relevant regulations of the study; one patient interrupted treatment due to death caused by other reasons, which was a dropout caused by irresistible factors. The above two situations are not related to the Chinese medicine preparation of the present invention itself. One case had itching after applying the ointment, and the itching was relieved after discontinuation, which was considered to be related to the test ointment.

[0186] 4.2 Analysis of baseline data

[0187] After excluding the dropout data, a total of 58 patients were included in the analysis. Patients aged 60 and above accounted for a large proportion, and most of them had a junior high school or lower education level. Since this study introduced subjective observation indicators such as the quality of life scale, common symptom scale, and pain score, and the lower education level may cause certain deviations in the research results, researchers need to give patients professional guidance during follow-up statistics to assist patients in completing the scale.

[0188] 4.3 Analysis of NCI-graded efficacy

[0189] Regarding the NCI graded efficacy, the efficacy of D14 was improved compared with D7, and the difference was statistically significant (P<0.05), but there was no significant difference in efficacy compared with D28 (P>0.05). Therefore, in order to shorten the research cycle in subsequent studies, the treatment time can be set to 2 weeks.

[0190] Subgroup analysis: Subgroup analysis was performed according to the drug treatment regimen: There was no significant difference in the efficacy of targeted drug-related HFSR and chemotherapy drug-related HFSR at each evaluation node (P>0.05), so we can determine that the Chinese medicine preparation of the present invention has a good efficacy for both. Subgroup analysis was performed according to the baseline NCI classification: The cure rate of grade II patients was significantly higher than that of grade I and grade III patients (P<0.05); when evaluated on D7 and D14, the effective rate of grade III patients was significantly higher than that of grade I and grade II patients, indicating that the average time for grade III patients to achieve effective relief of symptoms was shorter than that of grade I and grade II patients, which is consistent with the sharp decline in grade III patients at D7 in the figure. At D28, there was no significant difference in the effective rate of the three. Considering that grade I patients only had slight skin changes with abnormal sensations, which did not affect their daily life, they were weaker than grade III patients in the perception of symptom improvement. Their efficacy could only be evaluated by reaching the cure standard. Subsequent studies can only include patients ≥ grade II to make the research results more representative.

[0191] 4.4 Analysis of pain changes, quality of life, and common symptoms

[0192] Regarding pain changes and quality of life, the improvement on D14 was better than that on D7 (P<0.05), and the improvement on D28 was better than that on D14 (P<0.05), indicating that the long-term continuous use of the Chinese medicine preparation of the present invention is beneficial to further relieve pain and improve the quality of life of HFSR / HFSR patients. In addition, in addition to the burning sensation, the Chinese medicine preparation of the present invention has a good improvement effect on the common symptoms of HFSR / HFSR patients such as numbness, tingling, pain, insensitivity, erythema, desquamation, pigmentation, swelling, and ulcers (P<0.05).

[0193] 4.5 Analysis of the completion rate and safety of anti-tumor drugs

[0194] During the entire treatment process, the anti-tumor drug completion rate was 96.6%, and only one patient experienced an adverse reaction of itching, indicating that the Chinese medicine preparation of the present invention is safe and reliable for external use in the treatment of HFSR / HFSR, and can reduce the occurrence of patients interrupting treatment, changing medications, or being forced to reduce dosage due to intolerance to HFSR / HFSR, thereby further improving the anti-tumor treatment effect of patients.

[0195] 5. Typical Cases

[0196] (1) Patient Qin, male, 55 years old, gastric adenocarcinoma. Liver metastasis was found six months after surgery, and then he was treated with "sindilimab + white purple + tegafur" and "oxaliplatin + raltitrexed". After reviewing the condition, PD was found, and the third-line treatment was "apatinib 250mg qd". After two courses of treatment, HFSR occurred. When the patient was treated, his hands were red, swollen, cracked, and desquamated, accompanied by severe pain and swelling, which affected his dressing and half-clenched fists, and seriously affected his daily life. The NCI assessment grade was III. At the time of enrollment, he was still taking apatinib orally, and was given the Chinese medicine preparation of the present invention, which was applied to the affected area 3 times a day, and followed up every week.

[0197] After one week, all symptoms were improved.

[0198] Two weeks later, the patient's HFSR symptoms were significantly improved, especially desquamation and cracks, which were almost healed, with no swelling and pain, and slight pigmentation. The NCI grade was 0, which did not affect normal life. The patient successfully completed the follow-up treatment with apatinib at the original dose (therapeutic effect is shown in Figure 5 ).

[0199] (2) Patient Zhao, male, 76 years old, postoperative esophageal cancer. The current treatment regimen is "Tegafur 40mg bidd 1-14", which has been used for 7 cycles. HFSR occurred 140 days after the first medication. When he was diagnosed, he had erythema, blisters, and pigmentation on both feet, accompanied by severe pain, and an NRS score of 8 points, which affected his standing and walking; the NCI assessment grade was III. At the time of enrollment, he was given the Chinese medicine preparation of the present invention in addition to the Tegafur treatment, and was advised to apply it to the affected area 3 times a day, and follow up every week.

[0200] One week later, the blisters were relieved, the pain was reduced, and the NRS score was 3 points; it did not affect standing, but affected long-distance walking, and the NCI assessment grade was II. Two weeks later, the erythema of both hands had been removed, with pigmentation and slight desquamation, no pain, and no impact on the movement of both feet, and the NCI assessment grade was I (see the treatment effect Figure 6 ).

[0201] (3) Patient Gao, female, 50 years old. She underwent surgery for uterine leiomyoma on July 24, 2023. She was treated with "liposomal doxorubicin + anlotinib 4mg qd" after surgery. After 2 cycles, she developed hand-foot skin reactions. When she was diagnosed, she had erythema and desquamation on both hands, accompanied by severe pain, with an NRS score of 8 points, which affected her actions such as holding chopsticks and putting on and taking off clothes; her feet were red, swollen and desquamated, accompanied by swelling and pain, with an NRS score of 8 points, which affected her standing and walking; her NCI assessment grade was III. At the time of enrollment, she was given the Chinese medicine preparation of the present invention in addition to anlotinib treatment, and was advised to apply it to the affected area 3 times a day, and follow up every week.

[0202] Follow-up after 2 weeks showed that the erythema on both hands had been eliminated, there was slight desquamation, no pain, and no impact on the movement of both hands; there was slight desquamation on both feet, and the pain had been eliminated. The NCI assessment grade was I (see the treatment effect). Figure 7 ).

[0203] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for treating hand-foot skin reaction, characterized in that: The composition includes the following components in parts by weight: 50-150 parts of angelica sinensis, 50-150 parts of honeysuckle, 100-200 parts of knotweed, 40-80 parts of angelica dahurica, 20-60 parts of liquorice, 50-150 parts of lithospermum, 10-50 parts of frankincense, 10-50 parts of myrrh, and 5-15 parts of dragon's blood.

2. A Chinese medicine preparation for treating hand-foot skin reaction, characterized in that: Comprising the Chinese medicine composition according to claim 1 and excipients; The excipients are vaseline and ethylparaben solution; Or sesame oil and beeswax.

3. The method for preparing the Chinese medicine preparation according to claim 2, characterized in that: When the auxiliary materials are vaseline and ethylparaben solution, the preparation method is as follows: A. Mix angelica sinensis, honeysuckle, knotweed, angelica dahurica, liquorice and lithospermum officinale with 5 to 10 times the volume of 50 to 80% ethanol solution, reflux extraction 1 to 3 times, each time for 40 to 80 minutes, combine the extracts, and concentrate the extracts to a fluid extract with a relative density of 1.14 to 1.20; B. Freeze frankincense and dragon's blood, mix them, grind them, and sieve them to obtain frankincense-dragon's blood powder, grind myrrh separately, and sieve them to obtain myrrh powder; Or, frankincense and myrrh are crushed and sieved, 10 to 14 times the mass of ethanol with a volume concentration of 80 to 100% is added for percolation, the percolation liquid is collected, and concentrated to a relative density of 1.00 to 1.15 to obtain a frankincense-myrrh percolation concentrate, and dragon's blood is crushed and sieved to obtain dragon's blood powder; C. adding the fluid extract described in step A to 1500-2200 parts of melted vaseline for homogenization to obtain a matrix; D. mixing the frankincense-dragon blood powder, myrrh powder, ethylparaben solution and the matrix described in step B and cooling the mixture; Alternatively, the frankincense-myrrh percolated concentrate, dragon's blood powder, ethylparaben solution and the matrix described in step C are mixed and cooled to obtain the product.

4. The preparation method according to claim 3, characterized in that: The sieving is through a 100-200 mesh sieve.

5. The preparation method according to claim 3, characterized in that: The temperature of the vaseline is 45-60°C.

6. The preparation method according to claim 3, characterized in that: The mass ratio of the total amount of frankincense-dragon blood powder and myrrh powder to the ethyl hydroxybenzoate solution is 15-25:1, and the concentration of the ethyl hydroxybenzoate solution is 1-3%.

7. The preparation method according to claim 3, characterized in that: The concentration temperature in step B is 50-60°C.

8. A method for preparing the Chinese medicine preparation according to claim 2, characterized in that: When the auxiliary materials are sesame oil and beeswax, the preparation method is as follows: a. Soak Chinese angelica, honeysuckle, knotweed, angelica dahurica and licorice in 1500-2500 parts of sesame oil for 2-5 days; b. After soaking, heat to 100-160°C, hold for 20-60min, filter, and collect the liquid component; add lithospermum to the liquid component, heat to 140-180°C, fry for 10-30min, filter out the residue, and obtain filtered oil; c. Keep the oil temperature at 110-135°C, add 300-700 parts of beeswax, stir for 3-8 minutes until the beeswax is completely melted, and then cool to 40-55°C; d. Add crushed and sieved frankincense, dragon's blood and myrrh powder, stir well.

9. Use of the Chinese medicine composition according to claim 1 in preparing a medicament for treating hand-foot skin reaction.

Citation Information

Patent Citations

  • Pharmaceutical composition for treating ulcus cruris and preparation method thereof

    CN101648007A

  • Myogenic rubine collagen sponge drug as well as preparation method and application thereof

    CN104013760A

  • Medicine composition, preparation thereof and preparation method and application of preparation

    CN105434603A

  • Ointment for treating sore and ulcer and preparation method of ointment

    CN106728727A

  • Ointment for removing putrefaction and promoting tissue regeneration and preparation method thereof

    CN107982398A